AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 18, 2005

                                                     REGISTRATION NO. 333-112865
================================================================================


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                        POST-EFFECTIVE AMENDMENT NO. 1 TO
                                    FORM S-3
                             REGISTRATION STATEMENT
                                      UNDER
                           THE SECURITIES ACT OF 1933
                            ------------------------

                              ALFACELL CORPORATION
             (Exact name of registrant as specified in its charter)

           DELAWARE                       325410                 22-2369085
(State or other jurisdiction of      (Primary Standard        (I.R.S. Employer
incorporation or organization)          Industrial           Identification No.)
                                    Classification Code
                                          Number)

                              225 BELLEVILLE AVENUE
                          BLOOMFIELD, NEW JERSEY 07003
                                  (973)748-8082

    (Address, including zip code, and telephone number, including area code,
                  of registrant's principal executive offices)

                                 --------------

                                 KUSLIMA SHOGEN
                             CHIEF EXECUTIVE OFFICER
                              ALFACELL CORPORATION
               225 BELLEVILLE AVENUE, BLOOMFIELD, NEW JERSEY 07003
                                  (973)748-8082
            (Name, address, including zip code, and telephone number,
                   including area code, of agent for service)
                                 --------------

                                   COPIES TO:
                             KEVIN T. COLLINS, ESQ.
                              DORSEY & WHITNEY LLP
                    250 PARK AVENUE, NEW YORK, NEW YORK 10177
                                 (212) 415-9200

Approximate  date of  commencement  of proposed  sale to the public:  As soon as
practicable after this Registration Statement becomes effective.

If any securities  being  registered on this Form are to be offered on a delayed
or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box. |X|

If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the  Securities  Act  registration  statement  number of the  earlier  effective
registration statement for the same offering. |_|

If this Form is a  post-effective  amendment filed pursuant to Rule 462(c) under
the  Securities  Act,  check  the  following  box and  list the  Securities  Act
registration  statement number of the earlier effective  registration  statement
for the same offering. |_|

If this Form is a  post-effective  amendment filed pursuant to Rule 462(d) under
the  Securities  Act,  check  the  following  box and  list the  Securities  Act
registration  statement number of the earlier effective  registration  statement
for the same offering. |_|

If delivery  of the  prospectus  is  expected  to be made  pursuant to Rule 434,
please check the following box. |_|.

   THE  REGISTRANT  HEREBY  AMENDS THIS  REGISTRATION  STATEMENT ON SUCH DATE OR
   DATES AS MAY BE NECESSARY TO DELAY ITS  EFFECTIVE  DATE UNTIL THE  REGISTRANT
   SHALL  FILE  A  FURTHER  AMENDMENT  WHICH   SPECIFICALLY   STATES  THAT  THIS
   REGISTRATION  STATEMENT SHALL THEREAFTER  BECOME EFFECTIVE IN ACCORDANCE WITH
   SECTION  8(A)  OF THE  SECURITIES  ACT OF  1933  OR  UNTIL  THE  REGISTRATION
   STATEMENT  SHALL  BECOME  EFFECTIVE  ON SUCH DATE AS THE  COMMISSION,  ACTING
   PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.

   PURSUANT TO THE PROVISIONS OF RULE 429 UNDER THE SECURITIES ACT OF 1933, THIS
   REGISTRATION  STATEMENT  RELATES TO  REGISTRATION  STATEMENT NOS.  333-38136,
   333-89166 AND 333-111101 FILED BY THE REGISTRANT. THE PROSPECTUS FORMING PART
   OF THIS  REGISTRATION  STATEMENT,  IN ADDITION TO SERVING AS  PROSPECTUS  AND
   POST-EFFECTIVE  AMENDMENT TO  REGISTRATION  STATEMENT NO.  333-112865,  SHALL
   SERVE THE PURPOSE OF A  POST-EFFECTIVE  AMENDMENT TO  REGISTRATION  STATEMENT
   NOS. 333-38136, 333-89166 AND 333-11101 AS SPECIFIED IN RULE 429.



                                EXPLANATORY NOTE

       On September 9, 2004 Alfacell's  common stock began trading on the NASDAQ
SmallCap  Market.  Therefore,  Alfacell  is now  eligible  to use the  Form  S-3
registration  statement and accordingly is amending its  Registration  Statement
No. 333-112865,  which was originally filed and declared effective on a Form S-1
registration   statement,   with  this   Post-Effective  Form  S-3  registration
statement.

       Alfacell  has  previously  filed  three  Registration  Statements,   Nos.
333-38136,  333-89166 and 333-111101,  in order to register shares of its Common
Stock,  as well as shares of Common Stock  underlying  warrants  held by certain
selling  stockholders.  Pursuant to Rule 429 under the  Securities  Act of 1933,
this  Registration  Statement  also  serves  as a  post-effective  amendment  to
Registration   Statement  Nos.   333-38136,   333-89166  and  333-111101.   This
Post-Effective  Registration Statement eliminates those selling stockholders who
have sold shares  pursuant to such  Registration  Statements or pursuant to this
Registration  Statement and also eliminates  those selling  stockholders to whom
Alfacell no longer has registration obligations. On August 16, 2004, the Company
filed  post-effective  amendments  to  Registration  Statement  Nos.  333-38136,
333-89166 and 333-111101 and a pre-effective amendment to Registration Statement
No. 333-112865.  Of the 12,380,717 shares registered pursuant to such August 16,
2004 post-effective and pre-effective amendments, as of October 15, 2004, 86,500
shares have  either been sold  pursuant  to the  previously  filed  Registration
Statements  or  Alfacell  is  no  longer   required  to  register  such  shares.
Accordingly,   this  Post-Effective  Amendment  Registration  Statement  carries
forward from the four  previously  filed  Registration  Statements (i) 4,883,360
shares of Common  Stock and (ii)  7,410,857  shares of Common  Stock  underlying
warrants, for an aggregate of 12,294,217 shares of Common Stock.





THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY
NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER
TO SELL THESE SECURITIES AND WE ARE NOT SOLICITING OFFERS TO BUY THESE
SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.
================================================================================
SUBJECT TO COMPLETION, DATED January 18, 2005
PROSPECTUS

                              ALFACELL CORPORATION
                                12,294,217 Shares
                                  Common Stock
                                 ---------------

       Our  securityholders  named on page 15 of this prospectus are offering an
aggregate of 12,294,217 shares of our Common Stock.

       Our Common Stock is traded on the NASDAQ SmallCap Market under the symbol
"ACEL." On January 13, 2005, the reported last sale price of our Common Stock on
the NASDAQ SmallCap Market was $3.86 per share.

INVESTING IN OUR COMMON STOCK IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" BEGINNING ON PAGE 4.

       NEITHER THE  SECURITIES  AND  EXCHANGE  COMMISSION  NOR STATE  SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS  IS TRUTHFUL OR  COMPLETE.  ANY  REPRESENTATION  TO THE CONTRARY IS A
CRIMINAL OFFENSE.

                The date of this prospectus is January [__], 2005




                                TABLE OF CONTENTS

                                                                            PAGE

ALFACELL CORPORATION...........................................................1

SPECIAL NOTE REGARDING FORWARD  LOOKING STATEMENTS.............................3

RISK FACTORS...................................................................4

USE OF PROCEEDS...............................................................13

SELLING SECURITYHOLDERS.......................................................14

PLAN OF DISTRIBUTION..........................................................20

LEGAL MATTERS.................................................................21

EXPERTS.......................................................................21

WHERE YOU CAN FIND MORE INFORMATION...........................................23




                              ALFACELL CORPORATION

       We are a biopharmaceutical company primarily engaged in the discovery and
development of a new class of therapeutic  drugs for the treatment of cancer and
other pathological conditions. Based on our proprietary Ribonuclease,  or RNase,
which is a type of biological  enzyme that splits RNA molecules and is the basis
of our technology platform,  our drug discovery and development program consists
of novel  therapeutics  developed from amphibian  ribonucleases.  These are very
basic RNA enzymes which play important  roles in nature in the development of an
organism's  cells  and  in  cell  functions.  RNA is an  essential  bio-chemical
cellular  component  necessary to support life.  There are various types of RNA,
all of which have specific functions in a living cell. They help control several
essential  biological  activities,  namely  regulation  of  cell  proliferation,
maturation, differentiation and cell death. Therefore, they are ideal candidates
for the  development  of  therapeutics  for  cancer  and other  life-threatening
diseases, including HIV and autoimmune diseases, that require anti-proliferative
and apoptotic,  or programmed cell death,  properties.  We have co-sponsored and
been a key  participant in the  International  Ribonuclease  Meetings held every
three years.  This is a conference on all facets of research and  development in
connection  with  ribonucleases  that is attended by scientists  from around the
world.

       Alfacell  Corporation was incorporated in Delaware in 1981. Our corporate
headquarters is located at 225 Belleville Avenue,  Bloomfield,  New Jersey 07003
and our telephone number is (973) 748-8082.

                                    OVERVIEW
                                    --------

       ONCONASE(R), our trademark name for our flagship product, is currently in
an  international,  centrally  randomized Phase III trial. The first part of the
trial  has been  completed  and the  second  confirmatory  part of the  trial is
ongoing for which  patient  enrollment  is expected to be completed in the first
calendar quarter of 2005. The primary endpoint of the trial is survival,  and as
such, a sufficient  number of deaths must occur in order to perform the required
statistical  analyses to determine the efficacy of  ONCONASE(R) in patients with
unresectable (inoperable) malignant mesothelioma. If the results of the clinical
trials are positive, we expect to file for marketing registrations (NDA and MAA)
for  ONCONASE(R)  within six months of completion of the  statistical  analyses.
However, at this time, we cannot predict with certainty when a sufficient number
of deaths will occur to achieve statistical  significance.  Hence, the timing of
the  filing  is data  driven  as to when we will be able to file  for  marketing
registrations in the US and EU. Therefore, we cannot predict with certainty what
our total cost will be associated with obtaining  marketing  approvals,  or when
and if such approvals will be granted, and when actual sales will occur. We have
also conducted  other  randomized and  non-randomized  trials with patients with
advanced stages of solid tumors in other types of cancers.

       ONCONASE(R), unlike most cancer drugs that attack all cells regardless of
their phenotype (physical characteristics), malignant versus normal, and produce
a variety of severe  toxicities,  is not an  indiscriminate  cytotoxic,  or cell
killing  agent,  but rather,  its  activity  is  controlled  through  unique and
specific molecular  mechanisms.  ONCONASE(R) primarily affects extremely rapidly
growing malignant cells.  ONCONASE(R) is a novel amphibian ribonuclease,  unique
among the superfamily of pancreatic ribonuclease that has been isolated from the
eggs of the RANA  PIPIENS  frog,  commonly  called  the  leopard  frog.  We have
determined that thus far,  ranpirnase,  the generic name of ONCONASE(R),  is the
smallest known protein  belonging to the superfamily of pancreatic  ribonuclease
and has been shown, on a molecular level, to re-regulate the unregulated  growth
and proliferation of cancer cells.

       In December  2002,  we received Fast Track  Designation  from the FDA for
ONCONASE(R) for the treatment of malignant mesothelioma.  Fast Track Designation
is an FDA program designed to expedite the review of new drugs that are intended
to  treat  serious  or life  threatening  conditions  and that




demonstrate  the potential to address unmet medical needs.  In February 2001, we
received  an Orphan  Medicinal  Product  Designation  for  ONCONASE(R)  from the
European Agency for the Evaluation of Medicinal  Products,  or the EMEA.  Orphan
Medicinal  Product  Designation  is a program  designed  to  provide  marketing,
protocol and other incentives for pharmaceutical companies to develop and market
products in the European Community that address life threatening or very serious
conditions  that  affect  not more  than 5 in  10,000  persons  in the  European
Community.  Orphan  designation  in Europe  entitles  the Company to 10 years of
marketing  exclusivity,  reduced  filing fees and  regulatory  guidance from the
EMEA.

       These FDA and EMEA designations for ONCONASE(R) may serve to expedite its
regulatory review,  assuming the clinical trials yield a positive result. Future
clinical  trials,  however,  may not demonstrate  that ONCONASE(R) is effective.
Thus, our applications for FDA or EMEA approval to market ONCONASE(R), which are
dependent upon the success of our clinical trials, may be affected. The efficacy
and  safety of  ONCONASE(R)  for  malignant  mesothelioma,  will  ultimately  be
determined by the FDA. In the interim,  our Fast Track Designation  allows us to
continue to have  meetings and  discussions  with the FDA to establish  mutually
agreed upon parameters for the NDA to obtain marketing approval for ONCONASE(R),
based  on the  assumption  that  the  clinical  trials  will  continue  to yield
favorable results.

       Our drug  discovery  program  forms  the  basis  for the  development  of
specific  recombinant  RNases for chemically  linking drugs and other  compounds
such as monoclonal  antibodies,  growth  factors,  etc. and gene fusion products
with the goal of targeting  various molecular  functions.  This program provides
for joint design and  generation of new products with outside  partners.  We may
own these new  products  along with a  partner(s),  or we may grant an exclusive
license to the collaborating partner(s).

       We have also discovered  another series of proteins,  collectively  named
amphinases, that may have therapeutic uses. These proteins are bioactive in that
they have an effect on living cells and organisms and have both  anti-cancer and
anti-viral activity. All of the proteins characterized to date are RNases. These
products are  currently  undergoing  preclinical  testing.  We are  currently in
discussions with potential  pharmaceutical partners for the development of these
new compounds as conjugates and fusion proteins.

       We are engaged in the research,  development  and clinical  trials of our
products both independently and through research collaborations. Due to our lack
of  commercially  available  products,  we have  financed our  operations  since
inception through the sale of our equity  securities and convertible  debentures
in registered  offerings and private  placements.  Additionally,  we have raised
capital  through  debt  financings,  the sale of our tax  benefits  and research
products,  interest  income  and  financing  received  from our Chief  Executive
Officer. These funds provide us with the resources to acquire staff, facilities,
capital equipment,  finance our technology,  product development,  manufacturing
and clinical trials. We have incurred losses since inception and to date we have
not consummated any licensing, marketing or development arrangements. Presently,
our cash balance is sufficient to fund our expanded  operations at least through
October  31, 2005 based on our  expected  level of  expenditures  in relation to
activities  in  preparing  ONCONASE(R)  for  an NDA  filing  and  other  ongoing
operations  of the  company.  However,  we continue to seek  additional  capital
financing  through  the sale of equity in  private  placements,  sale of our tax
benefits and  exercise of stock  options and warrants but cannot be sure that we
will be able to raise capital on favorable terms or at all.

                                       2



                SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

       This  prospectus  and the documents  incorporated  by reference into this
prospectus  contain  forward-looking   statements  that  are  based  on  current
expectations,   estimates  and  projections  about  our  industry,  management's
beliefs,  and  assumptions  made by  management.  Words  such as  "anticipates,"
"expects,"  "intends," "plans," "believes," "seeks," "estimates," and variations
of  such  words  and  similar   expressions   are  intended  to  identify   such
forward-looking  statements.  These  statements  are not  guarantees  of  future
performance and are subject to certain risks, uncertainties and assumptions that
are difficult to predict;  therefore,  actual results may differ materially from
those expressed or forecasted in any forward-looking  statements.  The risks and
uncertainties  include those noted in "Risk  Factors" below and in the documents
incorporated by reference.

       We  undertake  no  obligation  to  update  publicly  any  forward-looking
statements, whether as a result of new information,  future events or otherwise,
except to the  extent  that we are  required  to do so by law.  We also may make
additional  disclosures in our Annual Report on Form 10-K,  Quarterly Reports on
Form  10-Q and  Current  Reports  on Form 8-K that we may file from time to time
with the Securities and Exchange  Commission,  or SEC.  Please also note that we
provide a cautionary  discussion  of risks and  uncertainties  under the section
entitled  "Risk Factors" in our Annual Report on Form 10-K.  These  descriptions
and  statements  are based on  management's  current  expectations.  Our  actual
results  may  differ   significantly   from  the  results   discussed  in  these
forward-looking  statements as a result of certain factors,  including those set
forth in the "Risk Factors" section and elsewhere in this prospectus.

                                       3



                                  RISK FACTORS

       AN  INVESTMENT  IN OUR COMMON  STOCK IS  SPECULATIVE  AND INVOLVES A HIGH
DEGREE OF RISK AND OUR  BUSINESS IS SUBJECT TO A NUMBER OF RISKS,  SOME OF WHICH
ARE DISCUSSED BELOW. OTHER RISKS ARE PRESENTED  ELSEWHERE IN THIS PROSPECTUS AND
IN THE  INFORMATION  INCORPORATED  BY  REFERENCE  INTO THIS  PROSPECTUS.  BEFORE
DECIDING TO INVEST IN OUR COMPANY OR TO  MAINTAIN OR INCREASE  YOUR  INVESTMENT,
YOU SHOULD  CAREFULLY  CONSIDER THE RISKS  DESCRIBED  BELOW,  IN ADDITION TO THE
OTHER INFORMATION  CONTAINED IN THIS PROSPECTUS,  OUR ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED JULY 31, 2004,  OUR QUARTERLY  REPORT ON FORM 10-Q FOR
THE FISCAL  QUARTER  ENDED  OCTOBER 31, 2004;  AND IN OUR OTHER FILINGS WITH THE
SECURITIES AND EXCHANGE COMMISSION (THE "SEC"), INCLUDING ANY SUBSEQUENT REPORTS
FILED ON FORMS 10-K, 10-Q AND 8-K. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR,
OUR BUSINESS AND OPERATING RESULTS COULD BE HARMED. THIS COULD CAUSE THE TRADING
PRICE  OF OUR  COMMON  STOCK  TO  DECLINE,  AND YOU MAY LOSE ALL OR PART OF YOUR
INVESTMENT.

RISK RELATED TO OUR COMPANY

WE HAVE  INCURRED  LOSSES  SINCE  INCEPTION  AND  ANTICIPATE  THAT WE WILL INCUR
CONTINUED LOSSES FOR THE FORESEEABLE  FUTURE. WE DO NOT HAVE A CURRENT SOURCE OF
PRODUCT REVENUE AND MAY NEVER BE PROFITABLE.

       We are a development  stage company and since our inception our source of
working  capital has been public and private  sales of our stock.  We incurred a
net loss of  approximately  $1,081,000  for the three months  ended  October 31,
2004.  We have  continued to incur losses since July 2004.  We may never achieve
revenue sufficient for us to attain profitability.

       We  incurred  net  losses of  approximately  $5,070,000,  $2,411,000  and
$2,591,000   for  the  fiscal  years  ended  July  31,  2004,   2003  and  2002,
respectively.

       Our  profitability  will  depend  on  our  ability  to  develop,   obtain
regulatory approvals for, and effectively market ONCONASE(R) as well as entering
into strategic  alliances for the  development of new drug  candidates  from the
out-licensing of our proprietary RNase technology.  The commercialization of our
pharmaceutical  products  involves  a  number  of  significant  challenges.   In
particular our ability to  commercialize  ONCONASE(R)  depends on the success of
our clinical development programs, our efforts to obtain regulatory approval and
our sales and  marketing  efforts or those of our  marketing  partners,  if any,
directed at physicians,  patients and  third-party  payors.  A number of factors
could affect these efforts including:

       o  Our ability to demonstrate  clinically  that our products have utility
          and are safe;

       o  Delays or refusals by  regulatory  authorities  in granting  marketing
          approvals;

       o  Our limited financial resources relative to our competitors;

       o  Our ability to obtain an appropriate marketing partner;

       o  The availability and level of reimbursement  for our products by third
          party payors;

       o  Incidents of adverse reactions to our products;

       o  Side effects or misuse of our products and unfavorable  publicity that
          could result; and

       o  The occurrence of manufacturing or distribution disruptions.

       We  will  seek to  generate  revenue  through  licensing,  marketing  and
development  arrangements  prior  to  receiving  revenue  from  the  sale of our
products.   To  date  we  have  not   consummated  any  licensing  or  marketing
arrangements  and we  may  not be  able  to  successfully  consummate  any  such
arrangements. We have entered into several development arrangements,  which have
resulted  in limited  revenues  for us.  However,  we cannot  ensure  that these
arrangements or future arrangements, if any, will result in

                                       4



significant amounts of revenue for us. We, therefore,  are unable to predict the
extent of any future losses or the time required to achieve profitability, if at
all.

WE NEED ADDITIONAL FINANCING TO CONTINUE OPERATIONS,  WHICH MAY NOT BE AVAILABLE
ON ACCEPTABLE TERMS, IF IT IS AVAILABLE AT ALL.

       We need additional financing in order to continue  operations,  including
completion of our current clinical trials and filing marketing registrations for
ONCONASE(R)  in the United  States with the FDA and in Europe with the EMEA.  If
the results from our current  clinical trial do not demonstrate the efficacy and
safety  of  ONCONASE(R)  for  malignant  mesothelioma,   our  ability  to  raise
additional capital will be adversely affected.  Even if regulatory  applications
for marketing approvals are filed, we will need additional financing to continue
operations.  In  connection  with the  recent  private  placement  from which we
realized $10.0 million in gross proceeds from an institutional investor, we plan
to expand our operations in preparing ONCONASE(R) for marketing registrations in
the US and outside the US as well as fund our ongoing operations. Presently, our
cash balance is  sufficient  to fund our expanded  operations  at least  through
October 31, 2005, based on our expected level of expenditures.  However,  taking
into consideration all of the uncertainties  related to drug development and our
industry,  we continue to seek additional  capital financing through the sale of
equity in private  placements,  sale of our net operating loss carryforwards and
exercise of stock  options and  warrants but cannot be sure that we will be able
to raise capital on favorable terms or at all.

WE MAY BE UNABLE TO SELL CERTAIN  STATE TAX BENEFITS IN THE FUTURE AND IF WE ARE
UNABLE TO DO SO, IT WOULD ELIMINATE A SOURCE OF FINANCING THAT WE HAVE RELIED ON
IN THE PAST.

       At July 31, 2004,  we had federal net  operating  loss  carryforwards  of
approximately  $47,326,000  that expire from 2005 to 2024.  We also had research
and  experimentation tax credit  carryforwards of approximately  $1,426,000 that
expire from 2005 to 2024. New Jersey has enacted legislation  permitting certain
corporations  located  in New Jersey to sell  state tax loss  carryforwards  and
state research and development credits, or net operating loss carryforwards,  in
order to  obtain  tax  benefits.  The  aggregate  amount of net  operating  loss
carryforwards that New Jersey allows corporations to sell each state fiscal year
(July 1st through June 30th) is  determined  annually and if New Jersey  reduces
such aggregate amount in any fiscal year we may be unable to sell some or all of
our  available  net  operating  loss  carryforwards  as we have in the past.  In
addition,  there is a limited  market for these types of sales and we may not be
able to find  someone to purchase our net  operating  loss  carryforwards  for a
reasonable price. Our historical results of operations have been improved by our
sale of net  operating  loss  carryforwards  and if we  continue  to  generate a
limited amount of revenue and are unable in the future to sell our net operating
loss carryforwards, our results of operations will be negatively impacted.

       For the state  fiscal year 2005 (July 1, 2004 to June 30,  2005),  we had
approximately  $1,335,000 total available net operating loss  carryforwards that
were saleable; of which New Jersey permitted us to sell approximately  $339,000.
We  received  approximately  $288,000  from  the  sale  of the  $339,000  of net
operating  loss  carryforwards,  which we  recognized  as tax  benefits  for the
quarter ended October 31, 2005.  For the state fiscal year 2004 (July 1, 2003 to
June 30, 2004), we had approximately $1,378,000 of total available net operating
loss carryforwards that were saleable;  of which New Jersey permitted us to sell
approximately  $261,000.  In December 2003, we received  approximately  $222,000
from the sale of the  $261,000 of net  operating  loss  carryforwards,  which we
recognized as tax benefits for the fiscal year ended July 31, 2004.

       If still  available  under New Jersey  law,  we will  attempt to sell the
remaining $996,000 of our net operating loss carryforwards, between July 1, 2005
and June 30,  2006.  This  amount,  which is a carryover  of our  remaining  net
operating  loss  carryforwards  from state fiscal year 2005,  may increase if we
incur

                                       5



additional net losses and research and  development  credits during state fiscal
year 2006. We can not  estimate,  however,  what  percentage of our saleable net
operating loss  carryforwards  New Jersey will permit us to sell, how much money
we will receive in connection  with the sale, if we will be able to find a buyer
for our net operating loss carryforwards or if such funds will be available in a
timely manner.

WE  CANNOT  PREDICT  HOW LONG IT WILL  TAKE US NOR HOW  MUCH IT WILL  COST US TO
COMPLETE OUR PHASE III TRIAL BECAUSE IT IS A SURVIVAL  STUDY AND WE ARE STILL IN
PATIENT ENROLLMENT IN PART TWO OF THIS PHASE III TRIAL.

       We currently  have ongoing a two-part Phase III trial of ONCONASE(R) as a
treatment for malignant  mesothelioma.  The first part of the clinical trial has
been  completed  and the second,  confirmatory  part is still  ongoing for which
patient  enrollment is expected to be completed in the first calendar quarter of
2005. The primary  endpoint of the Phase III clinical  trial is survival,  which
tracks the length of time patients enrolled in the study live.  According to the
protocol,  a sufficient  number of patient deaths must occur in order to perform
the required  statistical  analyses to determine the efficacy of  ONCONASE(R) in
patients with  unresectable  (inoperable)  malignant  mesothelioma.  Since it is
impossible to predict with certainty when these terminal events in the Phase III
trial will occur, we do not have the capability of reasonably determining when a
sufficient  number of deaths  will  occur,  nor when we will be able to file for
marketing registrations with the FDA and EMEA.

       In  addition,  clinical  trials are very costly and time  consuming.  The
length of time required to complete a clinical trial depends on several  factors
including the size of the patient population,  the ability of patients to get to
the site of the clinical study, and the criteria for determining  which patients
are  eligible  to join the study.  Delays in  patient  enrollment,  could  delay
achieving a sufficient number of deaths required for statistical analyses, which
therefore  may delay the marketing  registrations.  Although we believe we could
modify some of our  expenditures  to reduce our cash  outlays in relation to our
clinical trials and other NDA related expenditures,  we cannot quantify which or
the amount such expenditures might be modified. Hence, a delay in the commercial
sale of  ONCONASE(R)  would  increase  the time  frame  of our cash  expenditure
outflows and may require us to seek additional financing. Such capital financing
may not be available on favorable terms or at all.

       The FDA and comparable  regulatory  agencies in foreign  countries impose
substantial   pre-market   approval   requirements   on  the   introduction   of
pharmaceutical   products.  These  requirements  involve  lengthy  and  detailed
pre-clinical   and  clinical   testing  and  other  costly  and  time  consuming
procedures.  Satisfaction  of these  requirements  typically takes several years
depending on the type,  complexity  and novelty of the product.  We cannot apply
for FDA or EMEA approval to market ONCONASE(R) until the clinical trials and all
other registration requirements have been met.

IF WE FAIL TO OBTAIN THE NECESSARY REGULATORY APPROVALS,  WE WILL NOT BE ALLOWED
TO COMMERCIALIZE OUR DRUGS AND WILL NOT GENERATE PRODUCT REVENUE.

       The FDA and comparable  regulatory  agencies in foreign  countries impose
substantial   pre-market   approval   requirements   on  the   introduction   of
pharmaceutical   products.  These  requirements  involve  lengthy  and  detailed
pre-clinical   and  clinical   testing  and  other  costly  and  time  consuming
procedures.  Satisfaction  of these  requirements  typically takes several years
depending on the level of complexity  and novelty of the product.  Drugs in late
stages of clinical  development may fail to show the desired safety and efficacy
results  despite having  progressed  through  initial  clinical  testing.  While
limited  trials with our product have produced  certain  favorable  results,  we
cannot be certain that we will successfully  complete Phase I, Phase II or Phase
III  testing  of any  compound  within  any  specific  time  period,  if at all.
Furthermore,  the FDA or the company may suspend  clinical trials at any time on
various  grounds,  including a finding  that the  subjects or patients are being
exposed to an unacceptable health risk. In addition,  we cannot apply for FDA or
EMEA approval to market  ONCONASE(R) until pre-clinical and

                                       6



clinical  trials  have  been  completed.   Several  factors  could  prevent  the
successful  completion or cause significant  delays of these trials including an
inability  to enroll the required  number of patients or failure to  demonstrate
the product is safe and effective in humans.  Also if safety  concerns  develop,
the FDA and EMEA could stop our trials before completion.

       In December  2002, we received Fast Track  Designation  from the Food and
Drug  Administration,  or the FDA for ONCONASE(R) for the treatment of malignant
mesothelioma.  In  February  2001,  we  received  an  Orphan  Medicinal  Product
Designation  for  ONCONASE(R)  from the European  Agency for the  Evaluation  of
Medicinal Products, or the EMEA.

       All statutes and regulations governing the conduct of clinical trials are
subject to change by various  regulatory  agencies,  including  the FDA,  in the
future,  which could affect the cost and duration of our  clinical  trials.  Any
unanticipated costs or delays in our clinical studies would delay our ability to
generate product revenues and to raise additional  capital and could cause us to
be unable to fund the completion of the studies.

       We may not  market or sell any  product  for  which we have not  obtained
regulatory approval.  We cannot assure that the FDA or other regulatory agencies
will ever approve the use of our products that are under development. Even if we
receive  regulatory  approval,  such  approval  may involve  limitations  on the
indicated  uses for  which we may  market  our  products.  Further,  even  after
approval,  discovery of previously  unknown  problems could result in additional
restrictions, including withdrawal of our products from the market.

       If we fail to obtain the necessary regulatory approvals, we cannot market
or sell  our  products  in the  United  States,  or in other  countries  and our
long-term  viability  would  be  threatened.  If we fail to  achieve  regulatory
approval or foreign marketing  authorizations for ONCONASE(R) we will not have a
saleable product or product revenues for quite some time, if at all, and may not
be able to continue operations.

WE ARE AND WILL BE DEPENDENT UPON THIRD PARTIES FOR  MANUFACTURING OUR PRODUCTS.
IF THESE  THIRD  PARTIES  DO NOT DEVOTE  SUFFICIENT  TIME AND  RESOURCES  TO OUR
PRODUCTS OUR REVENUES AND PROFITS MAY BE ADVERSELY AFFECTED.

       We do not have the required  manufacturing  facilities to manufacture our
products.  We  presently  rely  on  third  parties  to  perform  certain  of the
manufacturing  processes for the production of  ONCONASE(R)  for use in clinical
trials.   Currently,   we  contract  with   Scientific   Protein  Labs  for  the
manufacturing  of ranpirnase  (protein drug substance) from the oocytes,  or the
unfertilized  eggs,  of the RANA PIPIENS  frog,  which is found in the Northwest
United  States and is commonly  called the leopard  frog.  We contract  with Ben
Venue  Corporation for the manufacturing of ONCONASE(R) and with Cardinal Health
for the labeling, storage and shipping of ONCONASE(R) for clinical trial use. We
utilize the services of these third party  manufacturers  solely on an as needed
basis with terms and prices customary for our industry.

       Our  use of  manufacturers  for  ranpirnase  and  ONCONASE(R)  have  been
approved  by  the  FDA.  We  have  identified  substantial  alternative  service
providers  for the  manufacturing  services for which we  contract.  In order to
replace an existing  service provider we must amend our IND to notify the FDA of
the new  manufacturer.  Although the FDA  generally  will not suspend or delay a
clinical  trial as a result of replacing an existing  manufacturer,  the FDA has
the  authority  to suspend or delay a clinical  trial if,  among other  grounds,
human subjects are or would be exposed to an unreasonable  and significant  risk
of illness or injury as a result of the replacement manufacturer.

                                       7



       We intend to rely on third  parties to  manufacture  our products if they
are  approved  for  sale  by  the  appropriate   regulatory   agencies  and  are
commercialized. Third party manufacturers may not be able to meet our needs with
respect to the timing, quantity or quality of our products or to supply products
on acceptable terms.

BECAUSE WE DO NOT HAVE MARKETING, SALES OR DISTRIBUTION CAPABILITIES,  WE EXPECT
TO CONTRACT  WITH THIRD  PARTIES FOR THESE  FUNCTIONS  AND WE WILL  THEREFORE BE
DEPENDENT UPON SUCH THIRD PARTIES TO MARKET, SELL AND DISTRIBUTE OUR PRODUCTS IN
ORDER FOR US TO GENERATE REVENUES.

       We currently have no sales,  marketing or distribution  capabilities.  In
order to commercialize any product candidates for which we receive FDA approval,
we expect to rely on established third party strategic partners to perform these
functions.  For example,  if we are successful in our Phase III clinical  trials
with ONCONASE(R),  and are granted marketing approval for the  commercialization
of  ONCONASE(R),  we will be unable to introduce  the product to market  without
establishing a marketing  collaboration with a pharmaceutical company with those
resources.  If we establish  relationships with one or more biopharmaceutical or
other marketing  companies with existing  distribution  systems and direct sales
forces to market any or all of our product candidates, we cannot assure you that
we will be able to enter into or maintain  agreements  with these  companies  on
acceptable terms, if at all. Further,  it is likely that we will have limited or
no control  over the manner in which  product  candidates  are  marketed  or the
resources devoted to such markets.

       In  addition,  we  expect  to  begin  to incur  significant  expenses  in
determining  our  commercialization  strategy with respect to one or more of our
product  candidates.  The determination of our  commercialization  strategy with
respect to a product candidate will depend on a number of factors, including:

       o  the  extent  to  which we are  successful  in  securing  collaborative
          partners to offset some or all of the funding obligations with respect
          to product candidates;

       o  the extent to which our agreement with our collaborators permits us to
          exercise  marketing  or  promotion  rights with respect to the product
          candidate;

       o  how our  product  candidates  compare  to  competitive  products  with
          respect  to  labeling,  pricing,  therapeutic  effect,  and  method of
          delivery; and

       o  whether  we  are  able  to  establish   agreements  with  third  party
          collaborators,  including large  biopharmaceutical  or other marketing
          companies, with respect to any of our product candidates on terms that
          are acceptable to us.

       A  number  of  these  factors  are  outside  of our  control  and will be
difficult to determine.

OUR PRODUCT CANDIDATES MAY NOT BE ACCEPTED BY THE MARKET.

       Even if approved by the FDA and other regulatory authorities, our product
candidates may not achieve market  acceptance,  which means we would not receive
significant  revenues  from  these  products.  Approval  by  the  FDA  does  not
necessarily  mean that the medical  community  will be convinced of the relative
safety,  efficacy  and  cost-effectiveness  of our products as compared to other
products.  In addition,  third party reimbursers such as insurance companies and
HMOs may be reluctant to reimburse expenses relating to our products.

                                       8



WE DEPEND UPON KUSLIMA SHOGEN AND OUR OTHER KEY PERSONNEL AND MAY NOT BE ABLE TO
RETAIN THESE EMPLOYEES OR RECRUIT QUALIFIED REPLACEMENT OR ADDITIONAL PERSONNEL,
WHICH WOULD HAVE A MATERIAL ADVERSE AFFECT ON OUR BUSINESS.

       We are highly  dependent upon our founder,  Chairman and Chief  Executive
Officer, Kuslima Shogen. Kuslima Shogen's talents, efforts, personality,  vision
and  leadership  have been,  and continue to be,  critical to our  success.  The
diminution or loss of the services of Kuslima Shogen, and any negative market or
industry  perception arising from that diminution or loss, would have a material
adverse  effect on our  business.  While our other  employees  have  substantial
experience  and have made  significant  contributions  to our business,  Kuslima
Shogen is our  senior  executive  and also our  primary  supporter  because  she
represents the Company's primary means of accessing the capital markets.

       Because  of  the  specialized  scientific  nature  of our  business,  our
continued  success  also is  dependent  upon our  ability to attract  and retain
qualified management and scientific personnel.  There is intense competition for
qualified  personnel  in the  pharmaceutical  field.  As our  company  grows our
inability  to  attract  qualified  management  and  scientific  personnel  could
materially  adversely  affect  our  research  and  development   programs,   the
commercialization of our products and the potential revenue from product sales.

       We do not have  employment  contracts  with Kuslima  Shogen or any of our
other management and scientific personnel.

RISK RELATED TO OUR INDUSTRY

OUR PROPRIETARY TECHNOLOGY AND PATENTS MAY OFFER ONLY LIMITED PROTECTION AGAINST
INFRINGEMENT AND THE DEVELOPMENT BY OUR COMPETITORS OF COMPETITIVE PRODUCTS.

       We own two  patents  jointly  with the United  States  government.  These
patents  expire in 2016. We also own ten United States  patents with  expiration
dates ranging from 2006 to 2019,  four European  patents with  expiration  dates
ranging from 2009 to 2016 and one Japanese  patent that expires in 2010. We also
own patent applications that are pending in the United States, Europe and Japan.
The scope of protection afforded by patents for  biotechnological  inventions is
uncertain,  and such uncertainty applies to our patents as well. Therefore,  our
patents may not give us competitive  advantages or afford us adequate protection
from competing products.  Furthermore, others may independently develop products
that are  similar  to our  products,  and may  design  around  the claims of our
patents.  Patent litigation and intellectual  property  litigation are expensive
and our resources are limited.  If we were to become involved in litigation,  we
might not have the funds or other resources  necessary to conduct the litigation
effectively.  This might prevent us from protecting our patents,  from defending
against  claims of  infringement,  or both.  To date,  we have not  received any
threats of litigation regarding patent issues.

DEVELOPMENTS BY COMPETITORS MAY RENDER OUR PRODUCTS OBSOLETE OR NON-COMPETITIVE.

       In February  2004, the Food and Drug  Administration  granted Eli Lilly &
Company  approval to sell its  Alimta(R)  medication  as an orphan drug to treat
patients with pleural mesothelioma.  Alimta is a multi-targeted  antifolate that
is  based  upon  a  different  mechanism  of  action  than  ONCONASE(R).  To our
knowledge,  no other company is developing a product with the same  mechanism of
action as  ONCONASE(R).  However,  there may be other  companies,  universities,
research  teams or  scientists  who are  developing  products  to treat the same
medical conditions our products are intended to treat. Eli Lilly is, and some of
these other  companies,  universities,  research teams or scientists may be more
experienced and have greater clinical, marketing and regulatory capabilities and
managerial and financial resources

                                       9



than we do. This may enable them to develop  products to treat the same  medical
conditions our products are intended to treat before we are able to complete the
development of our competing product.

       Our  business  is very  competitive  and  involves  rapid  changes in the
technologies  involved  in  developing  new drugs.  If others  experience  rapid
technological  development,  our products may become obsolete before we are able
to recover expenses  incurred in developing our products.  We will probably face
new competitors as new technologies  develop. Our success depends on our ability
to remain  competitive in the  development of new drugs or we may not be able to
compete successfully.

WE MAY BE SUED FOR PRODUCT LIABILITY.

       Our business  exposes us to potential  product  liability that may have a
negative  effect on our financial  performance and our business  generally.  The
administration  of drugs to humans,  whether in clinical trials or commercially,
exposes us to  potential  product  and  professional  liability  risks which are
inherent in the testing, production, marketing and sale of new drugs for humans.
Product  liability  claims  can be  expensive  to defend and may result in large
judgments or settlements  against us, which could have a negative  effect on our
financial  performance and materially adversely affect our business. We maintain
product  liability  insurance to protect our products and product  candidates in
amounts customary for companies in businesses that are similarly  situated,  but
our  insurance  coverage may not be  sufficient  to cover  claims.  Furthermore,
liability insurance coverage is becoming increasingly expensive and we cannot be
certain  that we will  always be able to  maintain  or  increase  our  insurance
coverage at an  affordable  price or in  sufficient  amounts to protect  against
potential losses. A product  liability claim,  product recall or other claim, as
well as any  claim for  uninsured  liabilities  or claim in  excess  of  insured
liabilities, may significantly harm our business and results of operations. Even
if a product  liability claim is not successful,  adverse publicity and time and
expense of defending such a claim may significantly interfere with our business.

IF WE ARE UNABLE TO OBTAIN FAVORABLE  REIMBURSEMENT FOR OUR PRODUCT  CANDIDATES,
THEIR COMMERCIAL SUCCESS MAY BE SEVERELY HINDERED.

       Our ability to sell our future  products  may depend in large part on the
extent to which  reimbursement  for the costs of our products is available  from
government  entities,  private health insurers,  managed care  organizations and
others.  Third-party payors are increasingly  attempting to contain their costs.
We cannot  predict  actions  third-party  payors may take,  or whether they will
limit the  coverage  and level of  reimbursement  for our  products or refuse to
provide any coverage at all.  Reduced or partial  reimbursement  coverage  could
make our  products  less  attractive  to  patients,  suppliers  and  prescribing
physicians and may not be adequate for us to maintain price levels sufficient to
realize an  appropriate  return on our  investment in our product  candidates or
compete on price.

       In some cases, insurers and other healthcare payment organizations try to
encourage the use of less expensive generic brands and over-the-counter, or OTC,
products  through  their   prescription   benefits  coverage  and  reimbursement
policies.  These  organizations may make the generic alternative more attractive
to the patient by providing  different  amounts of reimbursement so that the net
cost of the  generic  product  to the  patient  is less  than  the net cost of a
prescription  brand product.  Aggressive pricing policies by our generic product
competitors  and the  prescription  benefits  policies of insurers  could have a
negative effect on our product revenues and profitability.

       Many managed care  organizations  negotiate the price of medical services
and products and develop  formularies  for that purpose.  Exclusion of a product
from a formulary  can lead to its  sharply  reduced  usage in the  managed  care
organization  patient  population.  If our products  are not included  within an
adequate  number  of  formularies  or  adequate  reimbursement  levels  are  not
provided, or if those

                                       10



policies increasingly favor generic or OTC products,  our market share and gross
margins  could  be  negatively  affected,  as could  our  overall  business  and
financial condition.

       The  competition  among  pharmaceutical  companies to have their products
approved for  reimbursement  may also result in downward pricing pressure in the
industry  or in the  markets  where our  products  will  compete.  We may not be
successful in any efforts we take to mitigate the effect of a decline in average
selling prices for our products. Any decline in our average selling prices would
also reduce our gross margins.

       In addition,  managed care  initiatives  to control  costs may  influence
primary  care  physicians  to refer  fewer  patients  to  oncologists  and other
specialists.  Reductions in these referrals could have a material adverse effect
on the size of our potential  market and increase costs to  effectively  promote
our products.

       We are subject to new legislation,  regulatory proposals and managed care
initiatives  that may increase our costs of compliance and adversely  affect our
ability to market our products, obtain collaborators and raise capital.

       There have been a number of legislative and regulatory proposals aimed at
changing the healthcare system and pharmaceutical industry, including reductions
in the  cost of  prescription  products  and  changes  in the  levels  at  which
consumers   and   healthcare   providers   are   reimbursed   for  purchases  of
pharmaceutical  products.  For  example,  the  Prescription  Drug  and  Medicare
Improvement Act of 2003 which was recently enacted.  This legislation provides a
new  Medicare  prescription  drug benefit  beginning in 2006 and mandates  other
reforms.  Although  we cannot  predict the full  effects on our  business of the
implementation  of this new  legislation,  it is possible  that the new benefit,
which will be managed by private health insurers,  pharmacy benefit managers and
other managed care  organizations,  will result in decreased  reimbursement  for
prescription  drugs,  which may  further  exacerbate  industry-wide  pressure to
reduce the prices charged for prescription drugs. This could harm our ability to
market our  products  and  generate  revenues.  It is also  possible  that other
proposals  will be adopted.  As a result of the new Medicare  prescription  drug
benefit or any other proposals, we may determine to change our current manner of
operation, provide additional benefits or change our contract arrangements,  any
of which  could harm our  ability to operate our  business  efficiently,  obtain
collaborators and raise capital.

RISK RELATED TO THIS OFFERING

WE HAVE ONLY RECENTLY BEEN RELISTED ON THE NASDAQ  SMALLCAP MARKET AND OUR STOCK
IS THINLY  TRADED  AND YOU MAY NOT BE ABLE TO SELL OUR STOCK WHEN YOU WANT TO DO
SO.

       From April 1999,  when we were delisted from Nasdaq,  until  September 9,
2004,  when we  were  relisted  on the  Nasdaq  SmallCap  Market,  there  was no
established  trading  market for our common stock.  During that time, our common
stock was quoted on the OTC Bulletin  Board and was thinly  traded.  There is no
assurance  that we will be able to comply with all of the  listing  requirements
necessary to maintain relisted on the Nasdaq SmallCap Market.  In addition,  our
stock  remains  thinly  traded  and you may be unable to sell our  common  stock
during times when the trading market is limited.

THE PRICE OF OUR COMMON STOCK HAS BEEN, AND MAY CONTINUE TO BE, VOLATILE.

       The market price of our common stock, like that of the securities of many
other  development  stage  biotechnology  companies,  has fluctuated over a wide
range and it is likely that the price of our common stock will  fluctuate in the
future. Over the past three years, the sale price for our common stock,


                                       11



as reported by Nasdaq and the OTC Bulletin  Board has  fluctuated  from a low of
$0.18 to a high of  $10.07.  The  market  price  of our  common  stock  could be
impacted by a variety of factors, including:

       o  announcements of technological  innovations or new commercial products
          by us or our competitors,

       o  disclosure of the results of pre-clinical  testing and clinical trials
          by us or our competitors,

       o  disclosure of the results of regulatory proceedings,

       o  changes in government regulation,

       o  developments  in the  patents  or other  proprietary  rights  owned or
          licensed by us or our competitors,

       o  public concern as to the safety and efficacy of products  developed by
          us or others,

       o  litigation, and

       o  general market conditions in our industry.

       In addition,  the stock market continues to experience  extreme price and
volume  fluctuations.  These  fluctuations  have especially  affected the market
price  of many  biotechnology  companies.  Such  fluctuations  have  often  been
unrelated to the operating  performance of these companies.  Nonetheless,  these
broad market  fluctuations may negatively  affect the market price of our common
stock.

EVENTS  WITH  RESPECT TO OUR SHARE  CAPITAL  COULD CAUSE THE PRICE OF OUR COMMON
STOCK TO DECLINE.

       Sales of substantial  amounts of our common stock in the open market,  or
the  availability of such shares for sale,  could adversely  affect the price of
our common stock.  We had  34,994,514  shares of common stock  outstanding as of
October 31, 2004.  The following  securities  that may be exercised  for, or are
convertible  into,  shares of our common stock were issued and outstanding as of
October 31, 2004:

       o  Options.  Stock  options to  purchase  3,331,245  shares of our common
          stock at a weighted average exercise price of approximately  $3.56 per
          share.

       o  Warrants.  Warrants to purchase  11,564,853 shares of our common stock
          at a weighted average exercise price of approximately $2.52 per share.

       o  Convertible  Notes.  Notes which will convert into 1,424,822 shares of
          our common stock at an average conversion price of $0.25 per share and
          warrants which are  convertible  into  1,624,822  shares of our common
          stock at an exercise price of $1.00 per share.

       The shares of our  common  stock  that may be issued  under the  options,
warrants and upon conversion of the notes are currently  registered with the SEC
or are eligible for sale without any volume limitations  pursuant to Rule 144(k)
under the Securities Act.

OUR INCORPORATION  DOCUMENTS MAY DELAY OR PREVENT (I) THE REMOVAL OF OUR CURRENT
MANAGEMENT  OR  (II) A  CHANGE  OF  CONTROL  THAT  A  STOCKHOLDER  MAY  CONSIDER
FAVORABLE.

       We are currently authorized to issue 1,000,000 shares of preferred stock.
Our Board of Directors is authorized,  without any approval of the stockholders,
to issue the preferred  stock and  determine  the terms of the preferred  stock.
This  provision   allows  the  board  of  directors  to  affect  the  rights  of
stockholders, since the board of directors can make it more difficult for common
stockholders to replace members of the board.  Because the board of directors is
responsible for appointing the members of our management, these provisions could
in  turn  affect  any  attempt  to  replace  current  management  by the  common
stockholders. Furthermore, the existence of authorized shares of preferred stock
might have the effect of  discouraging  any  attempt  by a person,  through  the
acquisition  of a  substantial  number of shares of  common  stock,  to  acquire
control of our company. Accordingly, the accomplishment of a tender offer


                                       12



may be more difficult.  This may be beneficial to management in a hostile tender
offer, but have an adverse impact on stockholders who may want to participate in
the tender offer or inhibit a  stockholder's  ability to receive an  acquisition
premium for his or her shares.

THE ABILITY OF OUR STOCKHOLDERS TO RECOVER AGAINST ARMUS HARRISON & CO., OR AHC,
MAY BE LIMITED  BECAUSE WE HAVE NOT BEEN ABLE TO OBTAIN THE REISSUED  REPORTS OF
AHC WITH RESPECT TO THE FINANCIAL STATEMENTS INCLUDED IN THIS PROSPECTUS FOR THE
FISCAL YEAR ENDED JULY 31, 2004,  NOR HAVE WE BEEN ABLE TO OBTAIN AHC'S  CONSENT
TO THE USE OF SUCH REPORT THEREIN.

       Section 11 of the Securities  Exchange Act of 1934 (the  "Exchange  Act")
provides  that any  person  acquiring  or selling a security  in  reliance  upon
statements  set forth in a  registration  statement  may assert a claim  against
every  accountant  who has with its  consent  been named as having  prepared  or
certified  any part of the  registration  statement,  or as having  prepared  or
certified  any  report  or  valuation  that  is  used  in  connection  with  the
registration  statement,  if that part of the registration statement at the time
it is filed  contains a false or  misleading  statement of a material  fact,  or
omits a material  fact  required to be stated  therein or  necessary to make the
statements  therein not misleading (unless it is proved that at the time of such
acquisition such acquiring person knew of such untruth or omission).

       In June 1996, AHC dissolved and ceased all operations. Therefore, we have
not  been  able to  obtain  the  reissued  reports  of AHC with  respect  to the
financial  statements  included  in this  registration  statement  of which this
prospectus is a part nor have we been able to obtain AHC's consent to the use of
such report herein. As a result, in the event any persons seek to assert a claim
against AHC under  Section 11 of the Exchange Act for any untrue  statement of a
material fact contained in these financial  statements or any omissions to state
a material  fact  required to be stated  therein,  such  persons will be barred.
Accordingly, you may be unable to assert a claim against AHC under Section 11 of
the  Exchange  Act for any  purchases  of the  Company's  Common  Stock  made in
reliance  upon  statements  set forth in the Form 10-K for the fiscal year ended
July 31, 2004.  In addition,  the ability of AHC to satisfy any claims  properly
brought against it may be limited as a practical matter due to AHC's dissolution
in 1996.


                                USE OF PROCEEDS

       We will not receive  any  proceeds  from the sale of our Common  Stock in
this  offering.  Some of the shares of Common Stock to be sold in this  offering
have not yet been issued and will only be issued upon the  exercise of warrants.
We will receive estimated net proceeds of approximately  $25,173,314 if all such
warrants are  exercised.  However,  the warrants may not be exercised,  in which
event we would not receive any proceeds.  We intend to use any proceeds received
from the exercise of the warrants for general corporate purposes,  including the
funding of research and development  activities.  We expect to incur expenses of
approximately $40,000 in connection with this offering.

                                       13



                             SELLING SECURITYHOLDERS

       Alfacell  has  previously  filed  three  Registration  Statements,   Nos.
333-38136,  333-89166 and 333-111101,  in order to register shares of its Common
Stock,  as well as shares of Common Stock  underlying  warrants  held by certain
selling stockholders.  Pursuant to Rule 429 under the Securities Act of 1933, in
addition to serving as a post-effective  amendment to Registration Statement No.
333-112865,   this  Registration  Statement  also  serves  as  a  post-effective
amendment to Registration  Statement Nos.  333-38136,  333-89166 and 333-111101.
This  Registration  Statement  eliminates  those selling  stockholders  who have
previously  sold  shares  pursuant  to such  Registration  Statements  and  also
eliminates   those  selling   stockholders   to  whom  Alfacell  no  longer  has
registration  obligations.  On August 16, 2004, the Company filed post-effective
amendments to Registration  Statement Nos.  333-38136,  333-89166 and 333-111101
and a pre-effective  amendment to Registration Statement No. 333-112865.  Of the
12,380,717 shares registered pursuant to such August 16, 2004 post-effective and
pre-effective amendments, as of October 15, 2004, 86,500 shares have either been
sold pursuant to the previously filed Registration  Statements or Alfacell is no
longer  required to  register  such  shares.  Accordingly,  this  Post-Effective
Amendment  Registration Statement carries forward from the four previously filed
Registration  Statements (i) 4,883,360 shares of Common Stock and (ii) 7,410,857
shares of Common Stock  underlying  warrants,  for an  aggregate  of  12,294,217
shares  of  Common  Stock.  Alfacell  issued  such  shares  in  various  private
placements from February 2000 through May 2004.

       We are  required  to  maintain  the  effectiveness  of this  registration
statement for a period of two years from the date this registration statement is
declared  effective  or such  earlier  date  when all of the  shares  registered
hereunder have been sold or may be sold without volume  limitations  pursuant to
Rule 144(k) of the Securities Act of 1933, as amended.

STOCK OWNERSHIP

       The  table  below  sets  forth the  number  of  shares  of Common  Stock,
including  those  shares of Common  Stock  carried  forward  and  offered by the
selling  stockholders   pursuant  to  Registration   Statement  Nos.  333-38136,
333-89166 and 333-111101, that are:

       o  owned beneficially by each of the selling stockholders;

       o  offered by each selling stockholder pursuant to this prospectus;

       o  to be owned beneficially by each selling  stockholder after completion
          of the offering, assuming that all of the warrants and options held by
          the selling  stockholders  are exercised and all of the shares offered
          in this  prospectus are sold and that none of the other shares held by
          the selling stockholders, if any, are sold; and

       o  the  percentage  to  be  owned  by  each  selling   stockholder  after
          completion  of the  offering,  assuming  that all of the  warrants and
          options held by the selling  stockholders are exercised and all of the
          shares offered in this  prospectus are sold and that none of the other
          shares held by the selling stockholders, if any, are sold.

       For  purposes  of this  table  each  selling  stockholder  is  deemed  to
beneficially own:

       o  the shares of Common Stock  underlying  all warrants and options owned
          by the  selling  stockholders  as of  October  15,  2004 or which were
          exercisable  within 60 days after October 15, 2004,  unless  otherwise
          indicated; and

       o  the issued and outstanding shares of Common Stock owned by the selling
          stockholder as of October 15, 2004, unless otherwise indicated.

                                       14



       Because the  selling  stockholders  may offer all or some  portion of the
above-referenced  securities under this prospectus or otherwise, no estimate can
be  given  as to the  amount  or  percentage  that  will be held by the  selling
stockholders upon termination of any sale. In addition, the selling stockholders
identified  above may have sold,  transferred or otherwise  disposed of all or a
portion of such securities since the date on which  information in this table is
provided,  in  transactions  exempt from the  registration  requirements  of the
Securities Act.  Information about the selling stockholders may change from time
to time. Any changed information will be set forth in prospectus supplements, if
required.

       Except as otherwise  noted,  none of such persons or entities has had any
material relationship with us during the past three years.

       In connection with the registration of the shares of Common Stock offered
in this prospectus, we will supply prospectuses to the selling stockholders.



                                                               TOTAL SHARES
                                                                  BEING
                                                                 OFFERED       SHARES OWNED
                                               SHARES OWNED    PURSUANT TO         UPON        % OF SHARES
                                                 PRIOR TO          THIS       COMPLETION OF    OWNED AFTER
                 NAME(1)                        OFFERING(2)     PROSPECTUS       OFFERING      OFFERING(3)
--------------------------------------         ------------    -----------    -------------    -----------
                                                                                     
Anthony, Karen(4)                                 208,880         100,000         108,880           *
Bachrodt, Patrick M.(5)                           100,000         100,000               0           *
Basso Holdings, Ltd.(6)                           227,273         227,273               0           *
Beto, David(7)                                     32,500          32,500               0           *
Bowen Gas Corporation(8)                           92,000          92,000               0           *
Brown, Dennis(9)                                  163,800         100,000          63,800           *
Caasi, Krista J.(10)                                5,000           5,000               0           *
Caasi, Santiago(11)                               219,328          16,664         202,664           *
Conklin, Donald(12)                               460,500         110,000         350,500         1.00%
Danson, III Edward B. Family Trust(13)            120,000          50,000          70,000           *
DePeyster, Ashton(14)                             155,553          61,110          94,443           *
DePeyster, Margo(15)                               55,554          27,777          27,777           *
Dimzon, Delmer(16)                                 44,440          22,220          22,220           *
DKR Soundshore Strategic Holding Fund, Ltd(17)    227,273         227,273               0           *
DZS Computer Solutions, Inc.                      197,056          50,000         147,056           *
Europa International, Inc.(18)                  1,777,300       1,185,000         592,300         1.66%
Falkner, R. Jerry                                  52,342          52,342               0           *
Furno, Robert C. and Mary E. Furno(19)             26,000          25,000           1,000           *
Furst, Thomas(20)                                 100,000          80,000          20,000           *
Garg, Mukul(21)                                   180,012          55,556         124,456           *
Goodwin, Todd(22)                                  74,999          33,333          41,666           *
Gostine, Mark                                      90,000          90,000               0           *
Hamblett, Michael(23)                              17,819          13,819           4,000           *
Jacobson Living Trust(24)                         287,000         175,000         112,000           *
Kalista JTWROS, Clifford and Phyllis(25)           82,308          51,308          31,000           *


                                       15





                                                               TOTAL SHARES
                                                                  BEING
                                                                 OFFERED       SHARES OWNED
                                               SHARES OWNED    PURSUANT TO         UPON        % OF SHARES
                                                 PRIOR TO          THIS       COMPLETION OF    OWNED AFTER
                 NAME(1)                        OFFERING(2)     PROSPECTUS       OFFERING      OFFERING(3)
--------------------------------------         ------------    -----------    -------------    -----------
                                                                                     
Keating, A.J. Jr., M.D.                            70,000          40,000          30,000           *
Knoll Capital Fund II(26)                       1,621,880       1,185,000         436,880           *
Krogh, Jeffrey A.(27)                             275,000         200,000          75,000           *
Krogh, Sally J.(28)                               340,000         340,000               0           *
McCash Family Limited Partnership.(29)          7,671,331       1,506,570       6,164,761        15.36%
McCash, Donna M. Irrevocable Trust(30)          1,258,538         177,222       1,081,316         3.03%
McCash, James O.(31)                            2,678,032         120,000       2,558,032         7.19%
Muniz, Charles(32)                              1,395,714         642,857         752,857         2.11%
Muniz, Melba(33)                                1,032,714         392,857         639,857         1.81%
Neill, Carol(34)                                  154,200         120,000          34,200           *
Neill, Doug(35)                                   127,000          50,000          77,000           *
Number One Corporation                             53,876          53,876               0           *
Patton, Eve M.(36)                                656,667         266,667         390,000         1.11%
Pawl, Lawrence E.                                 100,000         100,000               0           *
Pisani, B. Michael(37)                             60,000          30,000          30,000           *
Plikerd, William D.(38)                           100,000         100,000               0           *
Provenzano, Matthew J.                             60,000          60,000               0           *
Samet, Roger(39)                                  420,000          50,000         370,000         1.06%
Schiro, Anthony(40)                               100,000          50,000          50,000           *
SF Capital Partners, Ltd.(41)                   2,095,354       3,125,574          11,638           *
Shogen, Kuslima(42)                             1,181,445         110,000       1,071,445         3.00%
Sitao, Janine(43)                                 156,660          33,330         123,330           *
Steger Family Foundation(44)                       55,556          55,556               0           *
Stadler, Martin                                   180,000         110,000          70,000           *
Theresa M. Provenzano Revocable Living             40,000          40,000               0           *
Trust U/A
Tweiten, Vicki K.(45)                              40,000          40,000               0           *
VFT Special Ventures Ltd.(46)                      60,533          60,533               0           *
Williams, Ira(47)                                 119,000         100,000          19,000           *
Wood, Scott                                        54,000          54,000               0           *
Zaumseil, Dean R.(48)                              97,000          97,000               0           *

         TOTAL                                 27,251,437      12,294,217      15,999,078


*      Represents less than one percent of Alfacell's outstanding Common Stock.

(1)    The last name of the individual selling stockholder is listed first.

(2)    Amounts  represented  include shares of Common Stock and shares of Common
       Stock underlying  warrants that were registered  pursuant to Registration
       Statements  Nos.  333-38136,  333-89166 and  333-111101.  Such shares are
       being  offered  pursuant to this combined  prospectus,  which serves as a
       post-effective   amendment   to  such   previously   filed   Registration
       Statements.

                                       16



(3)    The  percentage  of stock  outstanding  for each  stockholder  after  the
       offering is calculated by dividing (i) (A) the number of shares of Common
       Stock deemed to be  beneficially  held by such  stockholder as of October
       15, 2004,  minus (B) the number of shares being  offered in this offering
       by such stockholder (including shares underlying options and warrants) by
       (i) the sum of (A) the number of shares of Common Stock outstanding as of
       October 15, 2004 plus (B) the number of shares of Common  Stock  issuable
       upon the exercise of options and warrants held by such stockholder  which
       were exercisable as October 15, 2004 or which will be exercisable  within
       60 days after October 15, 2004 (including shares  underlying  options and
       warrants being offered in this offering).

(4)    Beneficial  ownership  includes an aggregate of 100,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(5)    Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(6)    Beneficial  ownership  includes an aggregate of 113,637  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(7)    Beneficial  ownership  includes an aggregate  of 20,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(8)    Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(9)    Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(10)   Beneficial  ownership  includes an  aggregate  of 5,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(11)   Beneficial  ownership  includes an aggregate of 200,664  shares of Common
       Stock underlying  warrants and options,  of which 16,664 shares are being
       offered pursuant to this  Registration  Statement.  Mr. Caasi is also the
       beneficial owner of an additional 5,000 shares of Common Stock underlying
       warrants  which  are held in the name of his  minor  daughter,  Krista J.
       Caasi.

(12)   Mr.  Conklin  is a member  of the  Board  of  Directors  of the  Company.
       Beneficial  ownership  includes an aggregate of 185,000  shares of Common
       Stock underlying  warrants and options, of which 110,000 shares are being
       offered pursuant to this Registration Statement.

(13)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(14)   Beneficial  ownership  includes an aggregate  of 61,110  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration  Statement.  Mr. DePeyster is also the beneficial owner
       of an  additional  27,777  shares of Common  Stock,  and 27,777 shares of
       Common Stock underlying  warrants which are held in the name of his wife,
       Margo DePeyster.  Mr.  DePeyster  disclaims  beneficial  ownership of the
       shares held in the name of his wife.

(15)   Beneficial  ownership  includes an aggregate  of 27,777  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.  Mrs. DePeyster is also the beneficial owner
       of an  additional  94,443  shares of Common  Stock,  and 61,110 shares of
       Common  Stock  underlying  warrants  which  are  held in the  name of her
       husband, Ashton DePeyster.  Mrs. DePeyster disclaims beneficial ownership
       of the shares held in the name of her husband.

(16)   Beneficial  ownership  includes an aggregate  of 22,220  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(17)   Beneficial  ownership  includes an aggregate of 113,637  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(18)   Beneficial  ownership  includes an aggregate of 592,500  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(19)   Beneficial  ownership  includes an aggregate  of 25,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(20)   Beneficial  ownership  includes an aggregate  of 40,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

                                       17



(21)   Beneficial  ownership  includes an aggregate  of 55,556  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(22)   Beneficial  ownership  includes an aggregate  of 33,333  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(23)   Beneficial  ownership  includes an aggregate  of 13,819  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(24)   Beneficial  ownership  includes an aggregate of 125,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(25)   Clifford and Phyllis Kalista of Clifford and Phyllis Kalista JTWROS,  are
       employees of a  broker-dealer  and purchased  all shares  covered by this
       prospectus  in the  ordinary  course of business  and, at the time of the
       purchase of the shares to be resold, had no agreements or understandings,
       directly or indirectly, with any person to distribute such shares.

       Beneficial  ownership  includes an aggregate  of 25,654  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(26)   Beneficial  ownership  includes an aggregate of 592,500  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(27)   Beneficial  ownership  includes an aggregate of 150,000  shares of Common
       Stock underlying  warrants and options, of which 100,000 shares are being
       offered pursuant to this  Registration  Statement.  Mr. Krogh is also the
       beneficial  owner of an additional  140,000  shares of Common Stock,  and
       200,000 shares of Common Stock underlying  warrants which are held in the
       name of his wife, Sally Krogh.

(28)   Beneficial  ownership  includes an aggregate of 200,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration  Statement.  Mrs. Krogh is also the beneficial owner of
       an additional 125,000 shares of Common Stock and 150,000 shares of Common
       Stock underlying warrants and options,  which are held in the name of her
       husband, Jeffrey Krogh.

(29)   Beneficial  ownership includes an aggregate of 5,149,769 shares of Common
       Stock  underlying  warrants,  of which 1,506,570 shares are being offered
       pursuant to this Registration Statement.

(30)   Beneficial  ownership  includes an aggregate of 688,019  shares of Common
       Stock  underlying  warrants,  of which  177,222  shares are being offered
       pursuant  to  this  Registration  Statement.  Mrs.  McCash  is  also  the
       beneficial  owner of an additional  2,108,170 shares of Common Stock, and
       569,862 shares of Common Stock underlying  warrants which are held in the
       name of her husband,  James  McCash.  Mrs.  McCash  disclaims  beneficial
       ownership of the shares held in the name of her husband.

(31)   Beneficial  ownership  includes an aggregate of 569,862  shares of Common
       Stock  underlying  warrants,  of which  120,000  shares are being offered
       pursuant  to  this  Registration  Statement.   Mr.  McCash  is  also  the
       beneficial  owner of an additional  570,519  shares of Common Stock,  and
       688,019 shares of Common Stock underlying  warrants which are held in the
       name of his wife,  Donna McCash  Irrevocable  Trust. Mr. McCash disclaims
       beneficial ownership of the shares held in the name of his wife.

(32)   Beneficial  ownership  includes an aggregate of 642,857  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement. Mr. Muniz is also the beneficial owner of an
       additional  639,857 shares of Common Stock,  and 392,857 shares of Common
       Stock  underlying  warrants which are held in the name of his wife, Melba
       Muniz. Mr. Muniz disclaims beneficial ownership of the shares held in the
       name of his wife.

(33)   Beneficial  ownership  includes an aggregate of 392,857  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration  Statement.  Mrs. Muniz is also the beneficial owner of
       an  additional  752,857  shares of Common  Stock,  and 642,857  shares of
       Common  Stock  underlying  warrants  which  are  held in the  name of her
       husband,  Charles Muniz. Mrs. Muniz disclaims beneficial ownership of the
       shares held in the name of her husband.

(34)   Beneficial ownership includes an aggregate of 60,000 shares of Common
       Stock underlying warrants, all of which are being offered pursuant to
       this Registration Statement. Mrs. Neill is also the beneficial owner of
       an additional 77,000 shares of Common Stock, and 50,000 shares of Common
       Stock underlying warrants which are held in the name of her husband, Doug
       Neill.

(35)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement. Mr. Neill is also the beneficial owner of an

                                       18



       additional  94,200  shares of Common  Stock,  and 60,000 shares of Common
       Stock  underlying  warrants which are held in the name of his wife, Carol
       Neill.

(36)   Beneficial  ownership  includes an aggregate of 266,667  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(37)   Beneficial  ownership  includes an aggregate  of 30,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(38)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(39)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(40)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(41)   SF Capital Partners Ltd., an affiliate of a broker-dealer,  purchased all
       shares covered by this prospectus in the ordinary course of business and,
       at the time of the purchase of the shares to be resold, had no agreements
       or understandings,  directly or indirectly, with any person to distribute
       such shares.

       Michael A. Roth and Brian J. Stark are the  founding  members  and direct
       the management of Staro Asset  Management,  L.L.C.,  a Wisconsin  limited
       liability  company  ("Staro").  Staro acts as investment  manager and has
       sole  power to direct the  management  of SF Capital  Partners,  Ltd.,  a
       British Virgin Islands company ("SF  Capital"),  which directly holds all
       of the shares of Common  Stock.  Through  Staro,  Messrs.  Roth and Stark
       possess  sole  voting and  dispositive  power  over all of the  foregoing
       shares.  Ownership  prior to the  offering  excludes an  aggregate of (i)
       852,273 shares of Common Stock  underlying  warrants issued to SF Capital
       on September 3, 2003 and (ii) 189,585  shares of Common Stock  underlying
       warrants  issued to SF Capital on January 29, 2004,  because the terms of
       such warrants  preclude SF Capital from  exercising the warrants if prior
       to  or  after  such  exercise,  SF  Capital  or  any  of  its  affiliates
       beneficially own or will own in excess of 4.99% of the outstanding shares
       of Common  Stock of the  Company.  The  852,273  shares  of Common  Stock
       underlying the September warrants were previously  registered pursuant to
       Registration  Statement No.  333-111101  and the 189,585 shares of Common
       Stock underlying the Additional Warrants are being registered pursuant to
       this Registration Statement.

(42)   Ms.  Shogen is Chairman of the Board and Chief  Executive  Officer of the
       Company.  Beneficial ownership includes an aggregate of 755,445 shares of
       Common Stock underlying warrants and options, of which 110,000 shares are
       being offered pursuant to this Registration Statement.

(43)   Beneficial  ownership  includes an aggregate of 108,330  shares of Common
       Stock underlying  warrants and options,  of which 33,330 shares are being
       offered pursuant to this Registration Statement.

(44)   Beneficial  ownership  includes an aggregate  of 55,556  shares of Common
       Stock underlying warrants all of which are being offered pursuant to this
       Registration Statement.

(45)   Beneficial  ownership  includes an aggregate  of 20,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(46)   VFT Special Ventures Ltd., an affiliate of a broker-dealer, purchased all
       shares covered by this prospectus in the ordinary course of business and,
       at the time of the purchase of the shares to be resold, had no agreements
       or understandings,  directly or indirectly, with any person to distribute
       such shares.

       Beneficial  ownership  includes an aggregate  of 60,533  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(47)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

(48)   Beneficial  ownership  includes an aggregate  of 50,000  shares of Common
       Stock  underlying  warrants,  all of which are being offered  pursuant to
       this Registration Statement.

                                       19



                              PLAN OF DISTRIBUTION

       We are  registering  for resale by the selling  stockholders  and certain
transferees a total of 12,294,217 shares of Common Stock, of which 4,883,360 are
issued and  outstanding  and up to  7,410,857  are  issuable  upon  exercise  of
warrants.

       The Selling Stockholders and any of their pledgees, donees, assignees and
successors-in-interest  may, from time to time,  sell any or all of their shares
of Common Stock on any stock exchange,  market or trading  facility on which the
shares  are traded or in private  transactions.  These  sales may be at fixed or
negotiated  prices.  The  Selling  Stockholders  may  use any one or more of the
following methods when selling shares:

       o  ordinary   brokerage   transactions  and  transactions  in  which  the
          broker-dealer solicits purchasers;

       o  block  trades  in which the  broker-dealer  will  attempt  to sell the
          shares as agent but may  position and resell a portion of the block as
          principal to facilitate the transaction;

       o  purchases  by  a   broker-dealer   as  principal  and  resale  by  the
          broker-dealer for its account;

       o  an  exchange   distribution  in  accordance  with  the  rules  of  the
          applicable exchange;

       o  privately negotiated transactions;

       o  short sales;

       o  broker-dealers  may  agree  with the  Selling  Stockholders  to sell a
          specified number of such shares at a stipulated price per share;

       o  a combination of any such methods of sale; and

       o  any other method permitted pursuant to applicable law.

       The Selling  Stockholders  may also sell shares  under Rule 144 under the
Securities Act, if available, rather than under this prospectus.

       Broker-dealers  engaged by the Selling Stockholders may arrange for other
brokers-dealers to participate in sales.  Broker-dealers may receive commissions
or discounts from the Selling  Stockholders  (or, if any  broker-dealer  acts as
agent  for the  purchaser  of  shares,  from the  purchaser)  in  amounts  to be
negotiated.  The  Selling  Stockholders  do not  expect  these  commissions  and
discounts to exceed what is customary in the types of transactions involved.

       The Selling Stockholders may from time to time pledge or grant a security
interest  in some or all of the Shares or Warrant  Shares  owned by them and, if
they default in the  performance of their secured  obligations,  the pledgees or
secured  parties  may offer and sell  shares of Common  Stock  from time to time
under this  prospectus,  or under an  amendment  to this  prospectus  under Rule
424(b)(3) or other  applicable  provision of the Securities Act of 1933 amending
the list of selling  stockholders  to include the pledgee,  transferee  or other
successors in interest as selling stockholders under this prospectus.

       Upon the Company being notified in writing by a Selling  Stockholder that
any material arrangement has been entered into with a broker-dealer for the sale
of Common Stock through a block trade, special offering,  exchange  distribution
or secondary  distribution or a purchase by a broker or dealer,  a supplement to
this prospectus  will be filed,  if required,  pursuant to Rule 424(b) under the
Securities Act,  disclosing (i) the name of each such Selling Stockholder and of
the participating  broker-dealer(s),  (ii) the number of shares involved,  (iii)
the  price  at which  such the  shares  of  Common  Stock  were  sold,  (iv) the
commissions paid or discounts or concessions  allowed to such  broker-dealer(s),
where  applicable,   (v)  that  such   broker-dealer(s)   did  not  conduct  any
investigation  to verify the information set out or incorporated by reference in
this prospectus, and (vi) other facts material to the transaction.  In addition,
upon the Company being notified in writing by a Selling Stockholder that a donee
or pledge intends to sell more

                                       20



than 500 shares of Common Stock, a supplement to this  prospectus  will be filed
if then required in accordance with applicable securities law.

       The Selling  Stockholders also may transfer the shares of Common Stock in
other circumstances, in which case the transferees, pledgees or other successors
in  interest  will  be the  selling  beneficial  owners  for  purposes  of  this
prospectus.

       The  Selling  Stockholders  and any  broker-dealers  or  agents  that are
involved  in selling  the shares may be deemed to be  "underwriters"  within the
meaning of the Securities Act in connection with such sales. In such event,  any
commissions  received  by such  broker-dealers  or agents  and any profit on the
resale  of the  shares  purchased  by  them  may be  deemed  to be  underwriting
commissions or discounts under the Securities Act. Each Selling Stockholders has
represented  and warranted to the Company that it does not have any agreement or
understanding,  directly or indirectly, with any person to distribute the Common
Stock.

       The  Company is  required  to pay all fees and  expenses  incident to the
registration  of the shares.  The Company  has agreed to  indemnify  the Selling
Stockholders against certain losses, claims, damages and liabilities,  including
liabilities under the Securities Act.

                                  LEGAL MATTERS

       The  validity  of the  shares to be offered  by this  prospectus  will be
passed upon for us by Dorsey & Whitney, LLP, New York, New York.

                                     EXPERTS

       Our financial  statements as of and for the years ended July 31, 2004 and
2003 and for the period from August 24, 1981 (the date of inception) to July 31,
2004, incorporated in this registration statement by reference from the Alfacell
Corporation  Annual  Report on Form 10-K for the year ended  July 31,  2004 have
been audited by J.H. Cohn LLP, independent registered public accounting firm, as
stated in their report,  which is incorporated herein by reference and have been
so  incorporated  in  reliance  upon the  report of such firm  given  upon their
authority as experts in  accounting  and  auditing.  The report of J.H. Cohn LLP
with  respect to our  financial  statements  from  inception to July 31, 2004 is
based on the reports of Armus  Harrison & Co. and KPMG LLP,  for the period from
inception to July 31, 2002.  As  discussed  in the Alfacell  Corporation  Annual
Report on Form 10-K for the year  ended  July 31,  2004,  Armus  Harrison  & Co.
ceased  performing  accounting and auditing services for the Company in 1993 and
subsequently dissolved and ceased all operations.

       The financial statements for the year ended July 31, 2002, and the period
from  August  24,  1981  (the date of  inception)  to July 31,  2002,  have been
incorporated by reference herein and in the  registration  statement in reliance
upon the report of KPMG LLP,  independent  registered  public  accounting  firm,
incorporated by reference herein, and upon the authority of said firm as experts
in accounting and auditing. The report of KPMG LLP with respect to our financial
statements  from  inception  to July 31,  2002 is based on the  report  of Armus
Harrison & Co.,  incorporated by reference herein, for the period from inception
to July 31, 1992. As discussed in the Alfacell Corporation Annual Report on Form
10-K for the year ended July 31, 2004,  incorporated by reference herein,  Armus
Harrison & Co.  ceased  performing  accounting  and  auditing  services  for the
Company in 1993 and subsequently dissolved and ceased all operations.

       The report of KPMG LLP  covering the July 31, 2002  financial  statements
contains an  explanatory  paragraph  that states that our recurring  losses from
operations,   working  capital  deficit  and

                                       21



limited liquid resources raise  substantial  doubt about our ability to continue
as a going concern. The financial statements do not include any adjustments that
might result from the outcome of that uncertainty.

       Alfacell  Corporation  has agreed to  indemnify  and hold KPMG LLP (KPMG)
harmless against and from any and all legal costs and expenses  incurred by KPMG
in successful  defense of any legal action or proceeding that arises as a result
of KPMG's consent to the  incorporation  by reference of its audit report on the
Company's  financial  statements  incorporated by reference in this registration
statement.

                                       22



                       WHERE YOU CAN FIND MORE INFORMATION

       We have  filed a  registration  statement  on Form  S-3  with  the SEC to
register  the  sale  of the  shares  of  Common  Stock  offered  by the  selling
shareholders  under the Securities Act. This prospectus,  which is a part of the
registration  statement,  does not contain all of the information that is in the
registration statement.  Statements made in this prospectus as to the content of
any contract,  agreement or other document are not  necessarily  complete.  Some
contracts,  agreements,  or  other  documents  are  filed  as  exhibits  to  the
registration  statement  or to a  document  incorporated  by  reference  in this
prospectus.  In those cases,  investors  should refer to such  exhibits for more
complete descriptions.

       We file annual,  quarterly  and special  reports,  proxy and  information
statements and other  information with the SEC. The public may read and copy, at
prescribed rates, any materials we file with the SEC, including the registration
statement and its exhibits and any documents incorporated by reference into this
prospectus,  at the SEC's offices at: Public  Reference  Room, 450 Fifth Street,
N.W.,  Washington,  D.C. 20549.  For information on how to obtain such documents
from the SEC,  investors  may  telephone  the  SEC's  Public  Reference  Room at
1-800-SEC-0330.  The SEC Internet site at http://www.sec.gov  contains materials
that we file with the SEC in  electronic  version  through the SEC's  Electronic
Data Gathering, Analysis and Retrieval (EDGAR) system.

       We are allowed by the SEC to "incorporate by reference" information filed
with the SEC, which means that we can disclose  important  information to people
by referring them to other  documents that we file with the SEC. The information
incorporated by reference is considered to be part of this  prospectus.  We have
filed the following  documents with the SEC pursuant to the Exchange Act and are
incorporating them by reference into this prospectus:

       (a)    the Company's Annual Report on Form 10-K for the fiscal year ended
              July 31, 2004;

       (b)    the Company's  Quarterly Report on Form 10-Q for the quarter ended
              October 31, 2004;

       (c)    the  Company's  Current  Reports on Form 8-K filed on September 9,
              2004 and November 26, 2004; and

       (d)    the  description  of Capital Stock  contained in our  Registration
              Statement on Form S-1 filed with the SEC (No. 333-112865).

       We also  incorporate  all  documents  we  subsequently  file with the SEC
pursuant to Section  13(a),  13(c),  14, or 15(d) of the  Exchange Act after the
date of this  prospectus  and prior to the  termination  of this  offering.  The
information in these documents will update and supersede the information in this
prospectus.

       You can  request  a copy of these  filings,  at no cost,  by  writing  or
telephoning us at the following address:

                              Alfacell Corporation
                              225 Belleville Avenue
                          Bloomfield, New Jersey 07003
                                  (973)748-8082



                                       23



                                     PART II

                     INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14.  OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

       The following table sets forth an itemized  estimate of fees and expenses
payable by the  Registrant  in  connection  with the offering of the  securities
described in this registration statement:

       SEC registration fee                                       $ 5,000
       Blue Sky                                                   $ 2,000
       Legal fees and expenses                                    $15,000
       Accounting fees and expenses                               $15,000
       Printing expenses                                          $ 1,000
       Miscellaneous                                              $ 2,000
                                                                  -------
                Total                                             $40,000
                                                                  =======
ITEM 15.  INDEMNIFICATION OF DIRECTORS AND OFFICERS

       Under the General Corporation Law of Delaware a corporation may indemnify
any  person  who was or is a party  or is  threatened  to be made a party to any
threatened,  pending or completed  action,  suit or  proceeding,  whether civil,
criminal,  administrative  or  investigative  (other than an action by or in the
right of the  corporation),  by  reason of the fact that he or she is or was our
director,  officer,  employee  or agent,  or is or was  serving  at our  request
against expenses (including attorneys' fees), judgments,  fines and amounts paid
in settlement  actually and reasonably  incurred in connection with such action,
suit or  proceeding  if he or she acted in good  faith and in a manner he or she
reasonably  believed to be in or not opposed to our best  interests,  and,  with
respect to any criminal action or proceeding, had no reasonable cause to believe
his or her conduct was unlawful.

       In addition,  the Delaware GCL also  provides  that we also may indemnify
any  person  who was or is a party  or is  threatened  to be made a party to any
threatened,  pending or completed action or suit by or in our right to procure a
judgment  in our  favor  by  reason  of the  fact  that  he or she is or was our
director,  officer,  employee or agent, or is or was serving at our request as a
director, officer, employee or agent of another corporation,  partnership, joint
venture,  trust or other enterprise against expenses (including attorneys' fees)
actually and reasonably incurred by him or her in connection with the defense or
settlement  of such  action  or suit if he or she  acted in good  faith and in a
manner  he or she  reasonably  believed  to be in or  not  opposed  to our  best
interests.  However,  in such an action by or on our behalf, no  indemnification
may be made in respect  of any claim,  issue or matter as to which the person is
adjudged  liable to us unless and only to the extent  that the court  determines
that,   despite  the   adjudication   of  liability  but  in  view  of  all  the
circumstances,  the person is fairly and  reasonably  entitled to indemnity  for
such expenses which the court shall deem proper.

       Our certificate of  incorporation is consistent with the Delaware GCL and
our by-laws provide that each of our directors,  officers,  employees and agents
shall be indemnified to the extent permitted by the Delaware GCL.

       We  have  entered  into  indemnification  agreements  with  each  of  our
directors.  The indemnity  agreements  are  consistent  with our by-laws and our
policy to  indemnify  directors  to the fullest  extent  permitted  by law.  The
indemnity  agreements  provide for  indemnification of directors for liabilities
arising out of claims  against  such  persons  acting as our  directors  (or any
entity  controlling,  controlled by or under common  control with us) due to any
actual or alleged breach of duty, neglect, error, misstatement,

                                      II-1



misleading  statement,  omission or other act done,  or  suffered or  wrongfully
attempted  by  such  directors,  except  as  prohibited  by law.  The  indemnity
agreements  also provide for the  advancement  of costs and expenses,  including
attorneys' fees,  reasonably incurred by directors in defending or investigating
any  action,  suit,  proceeding  or claim,  subject  to an  undertaking  by such
directors  to repay  such  amounts  if it is  ultimately  determined  that  such
directors are not entitled to  indemnification.  The indemnity  agreements cover
future acts and omissions of directors for which actions may be brought.

       The indemnity agreements also provide that directors, officers, employees
and agents are  entitled  to  indemnification  against all  expenses  (including
attorneys' fees) reasonably incurred in seeking to collect an indemnity claim or
to obtain  advancement  of expenses  from us. The rights of directors  under the
indemnity  agreements  are not exclusive of any other rights  directors may have
under Delaware GCL, any liability  insurance policies that may be obtained,  our
by-laws or  otherwise.  We would not be required to indemnify a director for any
claim based upon the director  gaining in fact a personal profit or advantage to
which such  director was not legally  entitled,  any claim for an  accounting of
profits made in connection  with a violation of Section 16(b) of the  Securities
Exchange  Act of 1934 or a similar  state or common law  provision  or any claim
brought about or contributed to by the dishonesty of the director.

       Insofar as indemnification  for liabilities  arising under the Securities
Act may be permitted to our directors, officers and controlling persons pursuant
to the  foregoing  provisions,  or  otherwise,  we have been advised that in the
opinion of the  Securities  and  Exchange  Commission  such  indemnification  is
against  public  policy as expressed in the  Securities  Act and is,  therefore,
unenforceable.  In the  event  that a claim  for  indemnification  against  such
liabilities  (other than the payment by the  registrant of expenses  incurred or
paid by a  director,  officer or  controlling  person of the  registrant  in the
successful  defense of any  action,  suit or  proceeding)  is  asserted  by such
director,  officer or controlling person in connection with the securities being
registered  we will,  unless in the  opinion of our  counsel the matter has been
settled by controlling precedent,  submit to a court of appropriate jurisdiction
the question  whether such  indemnification  by it is against  public  policy as
expressed in the Securities  Act and will be governed by the final  adjudication
of such issue.

ITEM 16.  EXHIBITS

                                                                       Filed
                                                                      Herewith
                                                                         or
Exhibit                                                            Incorporation
  No.   Item Title                                                  by Reference
------- ----------                                                 -------------

3.1     Certificate of Incorporation, dated June 12, 1981
        (incorporated by reference to Exhibit 3.1 to Registrant's
        Registration Statement on Form S-1, File No. 333-112865,
        filed on February 17, 2004)                                       *

3.2     Amendment to Certificate of Incorporation, dated February
        18, 1994 (incorporated by reference to Exhibit 3.2 to
        Registrant's Registration Statement on Form S-1, File No.
        333-112865, filed on February 17, 2004)                           *

3.3     Amendment to Certificate of Incorporation, dated December
        26, 1997 (incorporated by reference to Exhibit 3.3 to
        Registrant's Registration Statement on Form S-1, File No.
        333-112865, filed on February 17, 2004)                           *

3.4     Amendment to Certificate of Incorporation, dated January
        14, 2004 (incorporated by reference to Exhibit 3.4 to
        Registrant's Registration Statement on Form S-1, File No.
        333-112865, filed on February 17, 2004)                           *

3.5     Certificate of Designation for Series A Preferred Stock,
        dated September 2, 2003 (incorporated by reference to
        Exhibit 3.5 to Registrant's Registration Statement on Form
        S-1, File No. 333-112865, filed on February 17, 2004)             *

                                   II-2



                                                                       Filed
                                                                      Herewith
                                                                         or
Exhibit                                                            Incorporation
  No.   Item Title                                                  by Reference
------- ----------                                                 -------------
4.1     Securities Purchase Agreement and Warrant Agreement used in
        September 2003 private placement and Form of Warrant
        Certificate issued on January 16, 2004 and January 29, 2004
        to SF Capital Partners Ltd. (incorporated by reference to
        Exhibit 10.25 to Registrant's Annual Report on Form 10-K,
        filed on October 29, 2003)                                        *

4.2     Registration Rights Agreement used in September 2003
        private placement with SF Capital Partners Ltd.
        (incorporated by reference to Exhibit 10.26 to Registrant's
        Annual Report on Form 10-K, filed on October 29, 2003)            *

4.3     Form of Securities Purchase Agreement used in May 2004
        private placement with Knoll Capital Fund II, Europa
        International, Inc. and Clifford and Phyllis Kalista JTWROS
        (incorporated by reference to Exhibit 4.3 to Registration
        Statement on Form S-1, File No. 333-112865, filed on May
        18, 2004)                                                         *

4.4     Form of Registration Rights Agreement used in May 2004
        private placement with Knoll Capital Fund II, Europa
        International, Inc. and Clifford and Phyllis Kalista
        JTWROS (incorporated by reference to Exhibit 4.4 to
        Registration Statement on Form S-1, File No.
        333-112865, filed on May 18, 2004)                                *

4.5     Form of Warrant Certificate issued on May 11, 2004 to Knoll
        Capital Fund II, Europa International, Inc. and Clifford
        and Phyllis Kalista JTWROS (incorporated by reference to
        Exhibit 4.5 to Registration Statement on Form S-1, File No.
        333-112865, filed on May 18, 2004)                                *

5.1     Opinion of Dorsey & Whitney LLP (incorporated by reference
        to Exhibit 5.1 to Registration Statement on Form S-1, File
        No. 333-112865, filed on May 18, 2004)                            *

23.1    Consent of J.H. Cohn LLP                                          +

23.2    Consent of KPMG LLP                                               +

23.3    Consent of Dorsey & Whitney LLP (included in Exhibit 5.1)         *

*       Previously filed; incorporated herein by reference

+       Filed herewith

ITEM 17.  UNDERTAKINGS

       The undersigned registrant hereby undertakes:

       (1)    To file,  during  any  period  in which  offers or sales are being
made, a post-effective amendment to this registration statement:

              (i)    To include any prospectus  required by Section  10(a)(3) of
                     the Securities Act of 1933;

              (ii)   To reflect in the  prospectus  any facts or events  arising
                     after the effective date of the registration  statement (or
                     the most recent  post-effective  amendment  thereof) which,


                                      II-3



                     individually  or in the aggregate,  represent a fundamental
                     change in the  information  set  forth in the  registration
                     statement.  Notwithstanding the foregoing,  any increase or
                     decrease  in volume  of  securities  offered  (if the total
                     dollar value of  securities  offered  would not exceed that
                     which was  registered)  and any  deviation  from the low or
                     high end of the  estimated  maximum  offering  range may be
                     reflected  in  the  form  of  prospectus   filed  with  the
                     Commission  pursuant to Rule  424(b) if, in the  aggregate,
                     the changes in the volume and price  represent no more than
                     a 20% change in the maximum  aggregate  offering  price set
                     forth in the "Calculation of Registration Fee" table in the
                     effective registration statement;

              (iii)  To include any  material  information  with  respect to the
                     plan  of  distribution  not  previously  disclosed  in  the
                     registration  statement  or any  material  change  to  such
                     information in the registration statement;

provided,  however,  that  paragraphs  (1)(i)  and  (1)(ii)  do not apply if the
registration statement is on Form S-3, Form S-8 or Form F-3, and the information
required to be included in a  post-effective  amendment by those  paragraphs  is
contained in the periodic  reports filed with or furnished to the Securities and
Exchange Commission by the Registrant pursuant to Section 13 or Section 15(d) of
the Securities  Exchange Act of 1934 that are  incorporated  by reference in the
registration statement.

       (2)    That,  for the  purpose of  determining  any  liability  under the
Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the
offering of such  securities at that time shall be deemed to be the initial bona
fide offering thereof.

       (3)    To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.

       The  undersigned  registrant  hereby  undertakes  that,  for  purposes of
determining  any  liability  under  the  Securities  Act,  each  filing  of  the
registrant's  annual  report  pursuant to section  13(a) or section 15(d) of the
Exchange Act (and, where  applicable,  each filing of an employee benefit plan's
annual  report   pursuant  to  section  15(d)  of  the  Exchange  Act)  that  is
incorporated by reference in the registration  statement shall be deemed to be a
new registration  statement relating to the securities offered therein,  and the
offering of such  securities at that time shall be deemed to be the initial bona
fide offering thereof.

       Insofar as indemnification  for liabilities  arising under the Securities
Act of 1933 may be permitted to directors,  officers and controlling  persons of
the Registrant pursuant to the foregoing provisions or otherwise, the Registrant
has been advised that in the opinion of the Securities  and Exchange  Commission
such  indemnification  is against  public policy as expressed in the Act and is,
therefore,  unenforceable. In the event that a claim for indemnification against
such liabilities  (other than the payment by the Registrant of expenses incurred
or paid by a director,  officer or  controlling  person of the Registrant in the
successful  defense of any  action,  suit or  proceeding)  is  asserted  by such
director,  officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been  settled by  controlling  precedent,  submit to a court of  appropriate
jurisdiction the question whether such  indemnification  by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.

                                      II-4



                                   SIGNATURES

       Pursuant  to the  requirements  of Section 13 or 15(d) of the  Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                             ALFACELL CORPORATION
                                             Dated: January 18, 2005

                                             By:  /s/ KUSLIMA SHOGEN
                                                  ------------------------------
                                             Kuslima Shogen, Chief Executive
                                             Officer and Chairman of the Board



       Pursuant to the  requirements  of the Securities  Act, this  Registration
Statement has been signed by the following  persons in the indicated  capacities
on January 18, 2005.


/s/  Kuslima Shogen                                           *
---------------------------------------      -----------------------------------
Kuslima Shogen, Chief Executive              James J. Loughlin, Director
Officer, Principal Executive Officer
and Chairman of the Board


                   *                         /s/  Andrew Savadelis
---------------------------------------      -----------------------------------
John P. Brancaccio, C.P.A., Director         Andrew P. Savadelis, Director,
                                             Chief Financial Officer and
                                             Principal Financial Officer


                   *                                          *
---------------------------------------      -----------------------------------
Stephen K. Carter, M.D., Director            Paul M. Weiss, Ph.D., Director


                   *
---------------------------------------
Donald R. Conklin, Director


* The undersigned by signing her name hereto, does hereby sign this Registration
Statement or amendment  thereto on behalf of the above  indicated  directors and
officers of Alfacell  Corporation  pursuant to the power of attorney executed on
behalf of each such director.



/s/  Kuslima Shogen
---------------------------------------
Kuslima Shogen, Chief Executive Officer
and Chairman of the Board

                                      II-5



       KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Kuslima Shogen and Andrew P. Savadelis as
his or her true and lawful attorney-in-fact and agents, with full power of
substitution, for him or her and in his or her name, place and stead, in any and
all capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement (or any other registration statement
for the same offering that is effective upon filing pursuant to Rule 462(b)
under the Securities Act of 1933) and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and
Exchange Commission, hereby ratifying and confirming all that each of said
attorney-in-fact and agents, or his or her substitute or substitutes, may do or
cause to be done by virtue hereof. Pursuant to the requirements of the
Securities Act, this Registration Statement has been signed by the following
person in the indicated capacities on January 14, 2005.


/s/ DAVID SIDRANSKY, M.D.
---------------------------------------
David Sidransky, M.D., Director

                                      II-6


                                  EXHIBIT INDEX


23.1   Consent of J.H. Cohn LLP

23.2   Consent of KPMG LLP